{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:42:27Z","timestamp":1773286947114,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01467-1","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:03:27Z","timestamp":1773230607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of BIRC5 and MCL-1 as a potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-8312","authenticated-orcid":false,"given":"Jeremiah","family":"Pfitzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayak","family":"Chakravarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Mazumder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1560-7772","authenticated-orcid":false,"given":"Ujjal Kumar","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4046-7070","authenticated-orcid":false,"given":"Amit Kumar","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"1467_CR1","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1200\/JCO-25-00146","volume":"43","author":"TA Eyre","year":"2025","unstructured":"Eyre TA, Cheah CY, Sarkozy C, Kumar A, Le Gouill S. Mantle cell lymphoma: optimal treatment with Bruton tyrosine kinase-targeted approaches. J Clin Oncol. 2025;43:2300\u201310.","journal-title":"J Clin Oncol"},{"key":"1467_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00636-2","volume":"12","author":"H Kumar","year":"2022","unstructured":"Kumar H, Mazumder S, Chakravarti S, Sharma N, Mukherjee UK, Kumar S, et al. secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. Blood Cancer J. 2022;12:39.","journal-title":"Blood Cancer J"},{"key":"1467_CR3","doi-asserted-by":"crossref","unstructured":"Mazumder S, Mitra Ghosh T, Mukherjee UK, Chakravarti S, Amiri F, Waliagha RS et al. Integrating pharmacogenomics data-driven computational drug prediction with single-cell RNAseq to demonstrate the efficacy of a NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancer. Cancers (Basel). 2022;14:6009.","DOI":"10.3390\/cancers14236009"},{"key":"1467_CR4","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.4161\/cc.10.9.15486","volume":"10","author":"P Marcato","year":"2011","unstructured":"Marcato P, Dean CA, Giacomantonio CA, Lee PWK. Aldehyde dehydrogenase: Its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle. 2011;10:1378\u201384.","journal-title":"Cell Cycle"},{"key":"1467_CR5","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1158\/1078-0432.CCR-05-0267","volume":"11","author":"J Ying","year":"2005","unstructured":"Ying J, Srivastava G, Hsieh W-S, Gao Z, Murray P, Liao S-K, et al. The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res. 2005;11:6442\u20139.","journal-title":"Clin Cancer Res"},{"key":"1467_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2498-9","volume":"11","author":"U Anilkumar","year":"2020","unstructured":"Anilkumar U, Khacho M, Cuillerier A, Harris R, Patten DA, Bilen M, et al. MCL-1Matrix maintains neuronal survival by enhancing mitochondrial integrity and bioenergetic capacity under stress conditions. Cell Death Dis. 2020;11:321.","journal-title":"Cell Death Dis"},{"key":"1467_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrc3700","volume":"14","author":"Z Wang","year":"2014","unstructured":"Wang Z, Liu P, Inuzuka H, Wei W. Roles of F-box proteins in cancer. Nat Rev Cancer. 2014;14:233\u201347.","journal-title":"Nat Rev Cancer"},{"key":"1467_CR8","doi-asserted-by":"publisher","first-page":"16202","DOI":"10.1074\/jbc.M115.645978","volume":"290","author":"Z Mei","year":"2015","unstructured":"Mei Z, Zhang D, Hu B, Wang J, Shen X, Xiao W. FBXO32 targets c-Myc for proteasomal degradation and inhibits c-Myc activity. J Biol Chem. 2015;290:16202\u201314.","journal-title":"J Biol Chem"},{"key":"1467_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400305","volume":"11","author":"H Zhu","year":"2024","unstructured":"Zhu H, Wang J, Miao J, Shen M, Wang H, Huang X, et al. SNORD3A regulates STING transcription to promote ferroptosis in acute kidney injury. Adv Sci (Weinh). 2024;11:e2400305.","journal-title":"Adv Sci (Weinh)"},{"key":"1467_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature"},{"key":"1467_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122788","volume":"350","author":"G Siragusa","year":"2024","unstructured":"Siragusa G, Tomasello L, Giordano C, Pizzolanti G. Survivin (BIRC5): implications in cancer therapy. Life Sci. 2024;350:122788.","journal-title":"Life Sci"},{"key":"1467_CR12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","volume":"128","author":"J-N Gong","year":"2016","unstructured":"Gong J-N, Khong T, Segal D, Yao Y, Riffkin CD, Garnier J-M, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016;128:1834\u201344.","journal-title":"Blood"},{"key":"1467_CR13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/modpathol.2015.94","volume":"28","author":"Z Liu","year":"2015","unstructured":"Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A, et al. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology. 2015;28:1297\u2013314.","journal-title":"Modern Pathology"},{"key":"1467_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-020-00402-2","volume":"11","author":"MY Wang","year":"2021","unstructured":"Wang MY, Li T, Ren Y, Shah BD, Lwin T, Gao J, et al. MCL-1 dependency as a novel vulnerability for aggressive B cell lymphomas. Blood Cancer J. 2021;11:10\u201315.","journal-title":"Blood Cancer J"},{"key":"1467_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/1386207322666190916120128","volume":"22","author":"C Han","year":"2019","unstructured":"Han C, Yu X, Zhang C, Cai Y, Cao Y, Wang S, et al. Drug repurposing screen identifies novel classes of drugs with anticancer activity in mantle cell lymphoma. Comb Chem High Throughput Screen. 2019;22:483\u201395.","journal-title":"Comb Chem High Throughput Screen"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01467-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01467-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:03:28Z","timestamp":1773230608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01467-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01467-1","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have read the journal\u2019s policy on the disclosure of potential conflicts of interest. FL is the Founder and Chief Executive Officer (volunteer position without payment) of Canget BioTekpharma LLC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"28"}}